BCL2 and renal cell carcinoma: It was reported that (i) RNAi-mediated silencing of MCL-1 sensitized the Bcl-2 inhibitor ABT-737 to induce apoptosis in RCC cell lines [56]; (ii) a cell-permeable pyrrazolopyrimidine derivative (compound C) enhances TRAIL-induced apoptosis in human Caki renal cancer cells by reactive oxygen species (ROS)-mediated c-FLIP(L) and MCL-1 downregulation [57], and (iii) similar results were also found with anisomycin [58], dicoumarol [59], curcumin [60], YM155 [61] and the histone lysine-specific demethylase 1 inhibitor, SP2509 [62] in RCC cells.